PharmAthene, Inc. Message Board
-
considering the volatile market ride,,,jmo,g
-
just a mark 4 me
- Reply to
There is a bid for 100,000 shares of BSDM at $1.28, in the market right now
by canstic1 •2 hours 27 minutes agoalso with bout half the outstanding shares that clsn has and nearly half the float,,,numerous products ALREADY FDA APPROVED and being bought by the likes of CTCA and many teaching Hospitals,,todays pps is just pennies above CLSN,,,just agreein with canstic1 here,,pps won't stay here for long,,,jmo,gallen
-
87,344 @ 2:37 and on level 2 a 56,400 bid cinn @ 1.28
-
- Reply to
Interesting that both CLSN and BSD are currently @ $1.29 ...
by grleroy •Jun 18, 2013 3:54 PMthe especially neat thing 'bout BSD technology,,,is the Drs can see visual results from the procedure sooner,,,much sooner then waiting for oral meds to kick in,,,jmo,g
-
does the pill have ,,,say,,,ANY SIDE-EFFECTS???
-
,,,,But,,, a follow up Order from Terumo shortly After the exhibit would be a nice step in the right direction,,,time will tell,,,Grass-Hoppa
-
"Armando Anido, CEO of Nupathe said “Zecuity is the first and only FDA-approved migraine patch and is a game-changing treatment option for millions of patients who suffer from migraine headache pain and migraine-related nausea. We look forward to securing commercial partners and preparing for the launch of Zecuity, which is expected in the fourth quarter of this year.” The fact that NuPathe continues to negotiate for partners reflects a major lack of understanding in the greater pharmaceutical industry."
- Reply to
5/25/2013 @ 8:30AM |8,619 views Forbes: Big Pharma Learned The Wrong Marketing Lesson
by g_dargusch •9 hours agoBig pharma needs to learn to stay ahead of the marketing curve — to innovate ta"rgeted products for specific populations and to focus its marketing on those populations. Yet big pharma seems locked into the quest for billion dollar blockbuster drugs that can support large bureaucratic organizations.
One way big pharma can learn from companies like Google is to give old products new life by improving the products themselves or by improving the delivery systems of existing products. New delivery systems provide an opportunity for drug companies to repackage tried-and-true drugs and regain market exclusivity based on the innovative delivery process. That is what Google is doing with Google Glass. Glass delivers existing products, like mobile telephony, the Internet, global positioning systems and more, through a new, wearable system. In this case, Google is applying new technology to enhance the effectiveness of existing technology, something big pharma rarely does.
What big pharma shuns, little pharma sees as an opportunity. We have followed two companies with new delivery systems for previously approved drugs. These delivery systems make administration of the drug easier, increase the speed the drugs become effective, reduce side-effects and promise to deliver healthy revenues to their developers."
another company with a unique and new delivery system for already approved drugs. NuPathe created a system called SmartRelief. It delivers medication using iontophoresis, which transports molecules through the skin using mild electrical
stimulation. It is sometimes called an injection without a needle. The company’s lead product, ZECUITY, delivers sumatriptan, which became a generic drug in 2009, to treat acute cases of migraine with or without aura in adults. ZECUITY was approved by the FDA in January 2013 -
very interesting re-read,,,also to notice the pps been dropping since,,, in my OPINION, shares being accumulated,,,jmo,gallen
-
while the big three Green all day and PIP,, she a stuckka @ 1.59?
-
sorry wrong board,,,aginnnnnn
-
the big Three doing fine today but PIP stuck @ 1.59,,,TIA,,,gallen
-
- Reply to
Apricus could start run-up.. or not. Does it matter?
by robert.misovic •Jun 18, 2013 11:33 AMwith Vitaros already APPROVED in how many countries??? isn't TEN?
Vitaros bein APPROVED in 10 countries this stocks PP$ should be @ least $10!!!
.
June 10,,,,NEW YORK (AP) -- Apricus Biosciences Inc. said Monday that its impotence drug Vitaros has been approved in 10 European countries.
The company said Vitaros is now approved in the Netherlands, Germany, France, Italy, and the U.K., among other countries, for the treatment of erectile dysfunction. Apricus sought marketing approval for Vitaros in specific countries, and says the decentralized process was faster than seeking approval by the entire European Union
,this is jmo,gallen -
just sayin,,,I hope Bracco can deliver quicker
-
CLSN - As of 06/17/13, 01:06:01 PM: last Insider Transaction.
Buy: Blue Sell: Red
Non-meaningful transactions (gifts, grants, etc.) are automatically filtered out for quicker actions.
Buy(P) /
Sell(S) P/S date Filed Date Company Symbol Insider Relationship Share Amt. Unit Price Total Proceeds Shares Owned Return(1m) Details
P 2013-06-12 2013-06-12 10:26:37 Celsion CORP CLSN Tardugno Michael H CEO 10,000 $1.35 $13,457.00 223,285 - Reply to
APRI - As of 06/17/13, 01:03:04 PM: last 3 Insider Transactions.
by g_dargusch •Jun 17, 2013 1:04 PMsorry first day back and me make A bigga booBOO on Wrong board,,,sorry
-
APRI - As of 06/17/13, 01:03:04 PM: 12 Insider Transactions.
Sector: Healthcare Industry: Drug Manufacturers - Other
Prev Close:$2.79 Avg Vol(3m): 493,180 P/E: 0.00 EPS: -1.23
Email this page to a friend. Institutional Transactions for APRI
Buy: Blue Sell: Red
Non-meaningful transactions (gifts, grants, etc.) are automatically filtered out for quicker actions.
Buy(P) /
Sell(S) P/S date Filed Date Company Symbol Insider Relationship Share Amt. Unit Price Total Proceeds Shares Owned Return(1m) Details
P 2013-05-23 2013-05-24 16:53:04 APRICUS BIOSCIENCES, INC. APRI Ray Rusty director 5,000 $2.85 $14,250.00 28,852 view
P 2013-05-23 2013-05-24 16:50:40 APRICUS BIOSCIENCES, INC. APRI Pascoe Richard W CEO 35,000 $2.85 $99,750.00 35,000 view
P 2013-05-23 2013-05-24 16:46:38 APRICUS BIOSCIENCES, INC. APRI Martin Steven Robert CFO 20,000 $2.85 $57,000.00 20,000